Can Red Light Therapy Shrink Thyroid Nodules?

No published clinical trial has demonstrated that red light therapy, also called photobiomodulation or low-level laser therapy, shrinks thyroid nodules. The research that does exist on light therapy and the thyroid focuses almost entirely on autoimmune thyroiditis, where it has shown some promising effects on gland inflammation and overall thyroid volume. Nodule reduction and gland-volume reduction are not the same thing, and conflating the two is one of the most common misreadings of this literature.

Where the Claim Comes From

If you search for “red light therapy thyroid nodules,” you will find wellness sites and device manufacturers pointing to a handful of studies as evidence. The problem is that nearly all of those studies investigated photobiomodulation (PBM) in people with Hashimoto’s thyroiditis, an autoimmune condition where the immune system attacks the thyroid gland and causes it to become inflamed and enlarged. In Hashimoto’s, the gland itself swells, and reducing that swelling is a different physiological outcome from shrinking a discrete nodule, which is a growth of abnormal tissue within the gland.

A systematic review covering the use of PBM in chronic autoimmune thyroiditis found that across studies, PBM was associated with reductions in thyroid autoantibodies, improvements in thyroid hormone levels, and decreases in the dose of levothyroxine patients needed. Longer follow-up studies did report ultrasonographic changes in the gland, but these were changes to overall gland appearance, not disappearance of individual nodules.¹

The Thyroid Volume Finding That Gets Misquoted

The study most often cited to support the “PBM shrinks thyroid nodules” claim actually measured total thyroid gland volume, not individual nodule volume. In that trial, patients with euthyroid chronic autoimmune thyroiditis who received PBM saw their mean thyroid volume drop from about 15.9 mL at baseline to roughly 12.1 mL over the study period. That is a meaningful reduction. But the comparison group receiving antioxidant supplements alone saw no change, with volume hovering around 15.4 mL throughout.² This tells us something interesting about inflammation-driven gland swelling, but it does not tell us what happens to a solid or cystic nodule sitting inside that gland. A thyroid gland shrinking back toward its normal size after autoimmune inflammation is tamped down is fundamentally different from a nodule being broken down or absorbed.

One study that actually did track thyroid nodules directly used an LED device applied to the neck for cosmetic rejuvenation. Researchers performed serial ultrasounds and found no significant changes in the size or number of incidental thyroid nodules over the study period.³ That study was not designed to treat nodules, but it is one of the only datasets we have on what light therapy does, or rather does not do, to discrete nodules. The nodules simply stayed the same.

What PBM Does Seem to Do for the Thyroid

While the evidence for nodule shrinkage is essentially absent, the evidence for PBM’s effects on autoimmune thyroid inflammation is more encouraging, though still early-stage. In Hashimoto’s thyroiditis specifically, several trials have reported that PBM reduces thyroid peroxidase antibodies (TPOAb), the markers of the autoimmune attack on the gland. One study found a significant decrease in TPOAb levels in the PBM group compared to sham treatment, with the researchers attributing the change to PBM’s anti-inflammatory properties.⁴

The most striking finding across these studies is the reduction in levothyroxine dose. A pilot study of fifteen hypothyroid patients receiving ten sessions of low-level laser therapy found that the required levothyroxine dose dropped from an average of about 96 µg/day to 38 µg/day over nine months, and seven patients stopped needing supplements altogether. A follow-up randomized controlled trial with 43 patients confirmed the pattern: the laser group ended up needing roughly 39 µg/day compared to about 107 µg/day in the placebo group.⁵ These are small trials, and the effect sizes are large enough that replication in bigger, multi-center studies would be needed before drawing firm conclusions. But the direction of the findings has been consistent.

A parallel trial combining PBM with nutritional supplements in Hashimoto’s patients found improvements not just in antibody levels and thyroid hormone markers, but also in body weight, BMI, and waist-to-hip ratio compared to supplements alone.⁶ That suggests the therapy might help people feel better and function better, even if it is not dissolving nodules.

Quality of Life Effects

People with Hashimoto’s thyroiditis often deal with persistent fatigue, poor sleep, and cognitive fog even when their lab numbers look acceptable on paper. A recent study specifically examining PBM’s effect on these symptoms found that fatigue severity, sleep quality, daytime sleepiness, and behavioral status all improved significantly more in the active PBM group than in controls.⁷ If you have Hashimoto’s and are drawn to PBM, the honest sell is that it might ease symptoms and reduce autoimmune markers, not that it will shrink a nodule you are worried about.

Why Depth of Penetration Matters

The thyroid gland sits just below the skin of the neck, covered by thin muscle layers and connective tissue. That sounds close to the surface, but “close” in light therapy terms is still a challenge. Near-infrared light, the wavelength range used in most red light and PBM devices, loses energy rapidly as it travels through tissue. A study measuring the detectable depth of near-infrared autofluorescence through overlying neck tissue found an average penetration of about 1.2 mm, with a maximum of around 3 mm. Penetration was deeper through fat tissue (about 1.8 mm) and shallower through connective tissue (about 0.7 mm).⁸

That measurement was taken in a surgical context using a specific near-infrared imaging system, so it is not a perfect proxy for therapeutic PBM devices, which use different wavelengths and power levels. But it illustrates the core physics problem: light in the red and near-infrared range does not travel far through tissue. Clinical PBM studies on the thyroid typically use devices placed directly against the skin of the neck, sometimes with higher power densities than what consumer “red light panels” produce. If you are shining a low-power consumer device at your neck from several inches away, very little of that energy is reaching the thyroid, let alone reaching a nodule buried within it.

Red Light Therapy Is Not Thermal Ablation

A source of confusion is that thermal ablation procedures, which do shrink thyroid nodules very effectively, also use forms of energy delivered through the skin. Radiofrequency ablation, for example, involves inserting a needle electrode directly into the nodule under ultrasound guidance and heating the tissue to destroy it. This approach has demonstrated volume reductions of roughly a third to over half within a month, and over half to 85% at six months.⁹ Laser interstitial thermal therapy and microwave ablation work on similar principles, delivering concentrated heat directly into the nodule tissue.¹⁰

These procedures share the word “laser” or “energy” with red light therapy, but they operate on completely different mechanisms. Thermal ablation heats tissue to the point of coagulative necrosis, essentially cooking the nodule so the body reabsorbs the dead tissue over weeks. PBM uses light at orders of magnitude lower power, intended to stimulate cellular processes rather than destroy tissue. Expecting a PBM panel to shrink a nodule the way radiofrequency ablation does would be like expecting a heat lamp to cook a steak. The energy levels are not in the same universe.

Safety Considerations

One reasonable concern is whether shining red or near-infrared light at your neck could cause harm, particularly if a nodule turns out to be malignant. An animal study examining the safety of red light phototherapy on tissues harboring cancer found no measurable effect of low-level laser therapy on tumor growth, suggesting that PBM at typical therapeutic parameters does not appear to accelerate cancer.¹¹ The LED neck rejuvenation study mentioned earlier also found no harmful changes to thyroid gland structure, blood flow, or nodule characteristics over the study period.³

The safety picture is reassuring in a narrow sense: PBM probably will not make things worse. But the real safety risk is not from the light itself. It is from using PBM as a reason to delay proper evaluation of a nodule. A nodule that is growing, has suspicious ultrasound features, or causes symptoms needs diagnostic workup, not a consumer device.

Getting a Nodule Properly Evaluated

Thyroid nodules are extraordinarily common. Depending on the imaging method used, somewhere between a third and two-thirds of adults have at least one, and the vast majority are benign. The standard path for a suspicious nodule is ultrasound assessment followed, if warranted, by fine needle aspiration biopsy. Fine needle aspiration is a quick, low-risk procedure that provides cellular information to help determine whether a nodule is benign, indeterminate, or malignant.¹² That classification drives all further decisions: watch and wait, thermal ablation for a bothersome benign nodule, or surgery for something suspicious.

In the long-term follow-up of a PBM study in autoimmune thyroiditis patients, nodules were found in a few participants in both the treatment and placebo groups, and these were classified using the standard Bethesda system, with most being Bethesda II (benign).¹³ The presence of nodules in both groups reinforces the point that PBM does not prevent nodule formation or cause existing ones to vanish. Nodules have their own biology, and managing them requires their own evaluation pathway.

Why the Research Gap Exists

It is worth asking why there are no trials specifically testing PBM for thyroid nodule reduction. Part of the answer is practical: the existing thermal ablation techniques already work well for benign nodules that cause symptoms or cosmetic concerns, and they have a strong evidence base. Researchers studying PBM in the thyroid space have focused on autoimmune thyroiditis because that is where the biological rationale is strongest. PBM’s proposed mechanisms of action, reducing inflammatory cytokines and modulating immune cell behavior, map onto autoimmune conditions more naturally than onto the growth of discrete nodules, which are driven by cell proliferation and sometimes genetic mutations in the nodular tissue itself.

There is also a funding and incentive question. PBM research often comes from small academic groups without the resources for large-scale trials. The studies that exist on Hashimoto’s tend to involve 15 to 43 patients, far too few to establish definitive evidence even for the outcomes they do measure. Running a rigorous trial of PBM for nodule reduction would require ultrasound-confirmed nodules at baseline, randomization to treatment or sham, serial imaging over months, and enough participants to detect a meaningful change. That is expensive, and without strong preliminary data suggesting nodules respond to PBM, securing funding is difficult.

Home Devices Versus Clinical-Grade Equipment

The PBM studies reporting positive results in autoimmune thyroiditis used clinical-grade laser equipment, typically operating at 830 nm wavelength with carefully calibrated power densities and total energy doses. In the randomized controlled trial that demonstrated reduced levothyroxine requirements, the protocol delivered 707 J/cm² per session over ten sessions, with the device placed directly on the skin overlying the thyroid.⁵ Those are specific, high-fluence parameters delivered by a trained operator who knows the anatomy.

Consumer red light panels and handheld devices marketed for skin health, pain, or general “wellness” typically operate at lower power densities, emit light across broader wavelength bands, and are used at distances that dramatically reduce the energy reaching any particular tissue. The gap between a clinical PBM protocol targeting the thyroid and what a consumer device delivers to the neck is substantial. Even if PBM does modulate thyroid autoimmunity at the right dose, there is no guarantee a home device approaches that dose. And none of these home devices have been tested or approved for thyroid applications.

What People With Nodules Should Actually Consider

If you have a thyroid nodule and are researching your options, the decision tree depends on what the nodule is and what it is doing. Small, benign, asymptomatic nodules generally just get monitored with periodic ultrasound. Nodules that are large enough to cause compressive symptoms like difficulty swallowing, or that are cosmetically bothersome, can be treated with radiofrequency ablation, ethanol injection (for cystic nodules), or surgery depending on their characteristics. Suspicious or malignant nodules require surgical evaluation.

Red light therapy does not appear anywhere in clinical guidelines for thyroid nodule management, and based on the available evidence, there is no reason it should. If you have Hashimoto’s thyroiditis and are interested in PBM as an adjunct to your existing treatment, the early research is at least plausible enough to discuss with an endocrinologist, particularly given the consistent findings on antibody reduction and medication dose reduction. But that conversation should happen alongside standard care, not instead of it, and with realistic expectations about what has actually been shown in small trials versus what the internet claims.